Statera Biopharma, Inc. (STAB): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the companies striving to revolutionize immune health? What if there was a biopharmaceutical firm dedicated to restoring immune balance through innovative drug repurposing? Dive in to discover how Statera Biopharma Inc. (STAB) operates, from its unique approach to immune modulation to its strategic business model, and explore its mission to develop next-generation immune therapies.

Statera Biopharma Inc. (STAB), formerly Cytocom, Inc., is a clinical-stage biopharmaceutical company focused on creating novel immunotherapies. These therapies target autoimmune diseases, cancers, emerging viruses, and neutropenia/anemia. The company's approach is rooted in rebalancing the body's immune system and restoring homeostasis. Statera leverages a proprietary platform with a range of toll-like receptor (TLR) agonists, including TLR4 and TLR9 antagonists, and TLR5 agonists like Entolimod and GP532.

The company's mission is to restore immune health to patients with dysfunctional immune systems, repairing and revitalizing them to more effectively fight cancers, emerging viruses, and other diseases. Statera Biopharma develops its proprietary approach by identifying natural compounds that can be repurposed to serve as effective treatments, thereby reducing the risk associated with novel drug development. This model enables a focus on enhancing the body's natural healing pathways, positioning the firm as a noteworthy player in the field of immune health restoration.

Statera Biopharma, Inc. (STAB) History

Statera Biopharma, Inc. Founding Timeline

Year established

The company was originally incorporated in Delaware on April 9, 2008, under the name Cytocom, Inc.

Original location

While specific details regarding the original physical location of Cytocom, Inc. at its inception are not readily available in the provided search results, the company is currently located in Tampa, Florida.

Founding team members

Information about the specific founding team members of Cytocom, Inc. (now Statera Biopharma, Inc.) is not detailed in the provided search results.

Initial capital/funding

Details regarding the initial capital or funding of Cytocom, Inc. during its founding are not available in the provided search results.

Statera Biopharma, Inc. Evolution Milestones

Statera Biopharma, Inc. Transformative Moments

• Merger with Cleveland BioLabs: The merger significantly broadened the company's therapeutic pipeline and areas of focus, marking a pivotal shift in its strategic direction.
• Focus on Immune Modulation: A strategic emphasis on developing therapies that modulate the immune system to treat diseases, particularly with the STATegra platform.
• Registered Direct Offering and Private Placements: These financial activities provided crucial capital for Statera Biopharma to fund its operations, research and development efforts, and clinical trials.

To gain further insights into the company's guiding principles, you might find this resource helpful: Mission Statement, Vision, & Core Values of Statera Biopharma, Inc. (STAB).

Statera Biopharma, Inc. (STAB) Ownership Structure

Understanding the ownership structure of Statera Biopharma, Inc. provides key insights into who controls the company and whose interests are prioritized in strategic decision-making.

Statera Biopharma, Inc.'s Current Status

Statera Biopharma, Inc. is a public company, trading under the ticker symbol STAB. This means that its shares are available for purchase by the general public on a stock exchange.

Statera Biopharma, Inc.'s Ownership Breakdown

The ownership of Statera Biopharma is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. As of December 31, 2023, the most recent data available, the ownership breakdown is as follows:

Statera Biopharma, Inc.'s Leadership

The leadership team is responsible for the day-to-day operations and strategic direction of the company. Key members of the leadership team as of April 2025 include:

• Dr. Joseph Del Vecchio: President and Chief Executive Officer
• James Talton: Chief Financial Officer

For further insights into the company's financial standing, explore: Breaking Down Statera Biopharma, Inc. (STAB) Financial Health: Key Insights for Investors

Statera Biopharma, Inc. (STAB) Mission and Values

Statera Biopharma is dedicated to changing how people think about immunotherapy by restoring immune health. The company's principles manifest in its discovery, research, and development efforts, focusing on a 'BENEFIT/risk' approach that values the quality of life and future of those they treat.

Statera Biopharma's Core Purpose

Official mission statement

Statera Biopharma's mission is to restore immune health to patients with dysfunctional immune systems, repairing and revitalizing them to more effectively fight cancers, emerging viruses, and other diseases.

• The company focuses on developing novel immunotherapies.
• These therapies target autoimmune diseases, neutropenia/anemia, emerging viruses, and cancers.
• The approach is based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis.
• Statera leverages a Pan-TLR platform to develop therapies for multiple cancers, H1N1, influenza A, and autoimmune/inflammatory diseases.
• The company aims to build a world-leading immunology pipeline through collaborations and acquisitions.

Vision statement

Statera Biopharma envisions changing the way people think about immunotherapy.

• The company aims to restore diseased tissues to healthy phenotypes.
• They focus on BENEFIT/risk, valuing the quality of life and future of those they treat.
• Their approach involves leveraging complex pleiotropic beneficial effects.
• Statera embraces the idea that beneficial safe drugs act as natural analogs to resolve disease and elicit homeostasis.

Company slogan/tagline

Statera Biopharma: Restoring Immune Health.

• The company is dedicated to discovery and patients.
• They focus on healthy outcomes by promoting drugs that bring the immune system back into homeostasis.
• Statera develops its pipeline with guiding principles of restoration, balance, comprehensiveness, complexity, safety, and foresight.

For insights into the company's financial standing, you might find this resource helpful: Breaking Down Statera Biopharma, Inc. (STAB) Financial Health: Key Insights for Investors

Statera Biopharma, Inc. (STAB) How It Works

Statera Biopharma, Inc. focuses on developing and commercializing novel immunotherapies targeting autoimmune, inflammatory, and infectious diseases.

Statera Biopharma's Product/Service Portfolio

Statera Biopharma's Operational Framework

Statera Biopharma operates through a multi-faceted approach encompassing research, development, and strategic partnerships to advance its pipeline of immunotherapies:

• Drug Development: Statera Biopharma focuses on creating innovative therapies. Their lead compounds, like STAT-205 and STAT-201, are designed to modulate the immune system to treat diseases.
• Clinical Trials: Rigorous clinical trials are essential to test the safety and effectiveness of Statera Biopharma's drug candidates. These trials are conducted in phases to gather data and meet regulatory requirements.
• Strategic Collaborations: Statera Biopharma strategically collaborates with other companies and research institutions to expand its capabilities and accelerate drug development. These partnerships can provide access to new technologies, funding, and expertise.
• Intellectual Property: Protecting its innovations through patents and other intellectual property rights is a priority for Statera Biopharma. This helps maintain a competitive advantage and attract investment.

To gain more insights into the company's guiding principles, explore: Mission Statement, Vision, & Core Values of Statera Biopharma, Inc. (STAB).

Statera Biopharma's Strategic Advantages

Statera Biopharma possesses several strategic advantages that contribute to its competitive positioning and potential for success in the biopharmaceutical industry:

• Innovative Pipeline: A diverse pipeline of novel immunotherapies targeting significant unmet medical needs.
• Experienced Team: A management team with a proven track record in drug development and commercialization.
• Strategic Partnerships: Collaborations with leading research institutions and pharmaceutical companies.
• Strong Intellectual Property: A robust patent portfolio protecting its key technologies and drug candidates.

Statera Biopharma, Inc. (STAB) How It Makes Money

Statera Biopharma, Inc. focuses on developing and commercializing novel immunotherapies targeting autoimmune, inflammatory, and infectious diseases. It primarily generates revenue through licensing agreements, research grants, and, potentially in the future, the sale of pharmaceutical products.

Statera Biopharma, Inc.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, revenue streams are subject to change as products progress through development and commercialization. The table below represents a generalized estimation based on typical biotech revenue models.

Statera Biopharma, Inc.'s Business Economics

The business economics of Statera Biopharma, Inc. are characterized by:

• High R&D Costs: Significant investment in research and development is crucial for advancing drug candidates through clinical trials.
• Intellectual Property: Protecting its intellectual property through patents is vital for maintaining a competitive advantage and securing future revenue streams.
• Partnerships: Strategic alliances and partnerships with other pharmaceutical companies can provide financial support and expertise.
• Regulatory Approvals: Securing regulatory approvals from agencies like the FDA is essential for commercializing products and generating substantial revenue.

To delve deeper into the company's foundational principles, explore Mission Statement, Vision, & Core Values of Statera Biopharma, Inc. (STAB).

Statera Biopharma, Inc.'s Financial Performance

Key aspects of Statera Biopharma, Inc.'s financial performance include:

• Cash Runway: Monitoring cash reserves is critical to ensure sufficient funding for ongoing research and development activities.
• Operating Expenses: Managing operating expenses, including R&D and administrative costs, is essential for financial stability.
• Investment in Pipeline: The value of the company is closely tied to the progress and potential of its drug development pipeline.
• Market Capitalization: Market capitalization reflects investor confidence and the perceived value of the company's future prospects.

Statera Biopharma, Inc. (STAB) Market Position & Future Outlook

As of April 2025, Statera Biopharma faces a dynamic market landscape, navigating both opportunities for growth and potential challenges that could impact its future performance. For an in-depth look at the company's financials, see: Breaking Down Statera Biopharma, Inc. (STAB) Financial Health: Key Insights for Investors

Competitive Landscape

Opportunities & Challenges

Industry Position

Statera Biopharma operates within the competitive biotechnology and pharmaceutical industry, focusing on immune modulation therapies. Key aspects of its industry position include:

• Niche Focus: Statera carves out a specific niche by focusing on developing therapies that modulate the immune system to treat autoimmune and inflammatory diseases.
• Pipeline Development: The company's industry standing depends heavily on the success of its clinical trials and the progress of its drug development pipeline. Positive clinical data can significantly enhance its position.
• Partnerships: Strategic alliances and collaborations can boost Statera's visibility and credibility within the industry, providing access to resources and expertise.
• Market Access: Successfully navigating regulatory pathways and securing market access for approved therapies are critical for establishing a strong industry position.